One of the exciting and frustrating things about convergence, particularly in healthcare, is that it’s tough to predict how the hybrid technologies will find their way to market. The process of reaching that goal is filled with unexpected obstacles, twists and pivots.
Clinical trials offer a great example of how bipharma companies are making use of digital health devices and online social media to make drug development more efficient. In an interview with MedCity News at the BIO2015 conference in Philadelphia this week, Dr. Eric Topol called attention to the work being done applying digital health to reduce the cost of clinical trials, which would clear the way to lower drug prices.
